title: Epidemiological significance of bufexamac as a frequent and relevant contact sensitizer.
abstract: Bufexamac-containing ointments and creams are widely used by many patients with eczematous disorders as an alternative to topical corticosteroids. Recent studies provide evidence of a notable prevalence of contact sensitization in patch test populations. The aim of this study was to assess the frequency of use of this topically-applied drug by eczema patients in general, and to evaluate its potential to cause allergic contact reactions. 500 routinely patch tested patients (f:m = 377:123) were tested with bufexamac 5% and Parfenac ointment (the only commercial product available in Austria) in addition to the standard and other series of the German Contact Dermatitis Group. The packaging of the commercial product was shown to the entire study population, to decide whether or not they had ever used this product. In addition, their general practitioner was contacted to verify the anamnestic data. A total of 30 patients agreed that they had definitely used bufexamac, 5 others having probably applied it. The indication for and the duration of treatment were noted. Positive and relevant patch test reactions to bufexamac, as well as the bufexamac-containing ointment, were seen in 20 out of these 35 patients (57%), and sensitization occurred even after short-term application. Our study demonstrates that bufexamac has to be assumed to be a topical drug with a very high sensitization rate in an unselected patch test population (4% of 500 patients), and should therefore be added to the standard series.
authors.affiliation: Department of Dermatology, University of Graz, Austria.
authors.forename: B
authors.initials: B
authors.lastname: Kränke
authors.forename: C
authors.initials: C
authors.lastname: Szolar-Platzer
authors.forename: P
authors.initials: P
authors.lastname: Komericki
authors.forename: J
authors.initials: J
authors.lastname: Derhaschnig
authors.forename: W
authors.initials: W
authors.lastname: Aberer
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002019:Bufexamac / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D017449:Dermatitis, Allergic Contact / Q000453:epidemiology* / Q000209:etiology; D004485:Eczema / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010328:Patch Tests; D015995:Prevalence; D011379:Prognosis; D011446:Prospective Studies
chemical_list: D000893:Anti-Inflammatory Agents; D002019:Bufexamac